Greenland Mines Outlines $2B Valuation for Sarfartoq Project

Greenland Mines Provides Progress Update on 2026 Field Programs at Skaergaard and Sarfartoq

Greenland Mines completed its 2026 bulk-sampling program at the Skaergaard palladium-platinum-gold project in East Greenland, collecting 104.8 tons of mineralized material from seven sites—exceeding the original plan. Simultaneously, the company opened its exploration camp at the Sarfartoq rare earth element project in West Greenland and initiated structural mapping and environmental baseline studies, building on the project's compelling Initial Assessment showing a pre-tax NPV of approximately US$2.05 billion and IRR of 118.6%.

Greenland Mines Says Now In Full Compliance With Nasdaq Listing Requirements; Sets Biotechnology Division Spin-Off For Q4 2026

Greenland Mines Says It Received Government Of Greenland Approval For Sarfartoq License Transfer, Expects To Close $35M Neo North Star Resources Acquisition Before September 1

Dow Falls Over 150 Points; JM Smucker Shares Gain Following Upbeat Q1 Earnings

Dow Jones fell 150 points, NASDAQ declined 0.27%, and S&P 500 dropped 0.07%. Industrials shares jumped 1% while consumer discretionary stocks fell 0.7%. J.M. Smucker Co reported better-than-expected earnings and raised FY27 guidance. Equities mostly up in Asia and Europe.

NeoGenomics shares are trading higher after the company announced that its RaDaR ST molecular residual disease assay has received expanded coverage from the Centers for Medicare & Medicaid Services' Molecular Diagnostic Services Program.

NeoGenomics’ RaDaR ST Molecular Residual Disease Assay Receives Expanded Coverage From CMS’ MolDX To Include Immunotherapy Monitoring For Patients With Late-Stage Solid Tumors

New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuumNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions